Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 14, 2008

CHDI to Provide $37M to Evotec in Collaboration Extension

  • Evotec signed a collaboration extension with CHDI Foundation, an organization focused on Huntington’s disease (HD). The foundation will pay up to $37 million in research fees related to this partnership, which will be in effect to the end of 2010.

    Terms of the agreement cover Evotec's biochemical and cellular assay development and high-content screening on interesting cell lines with the aim of identifying novel starting points for medicinal chemistry programs. Additionally, Evotec will continue to supply key support in the area of medicinal chemistry and biology optimization on multiple biological targets for the treatment of HD as the company generates lead molecules for subsequent progression into clinical trials.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »